Skip to main content
Top
Published in: Clinical Rheumatology 8/2010

01-08-2010 | Original Article

The Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) and their correlation with main symptoms experienced by patients with spondyloarthritis

Authors: Euthalia Roussou, Shahzabeen Sultana

Published in: Clinical Rheumatology | Issue 8/2010

Login to get access

Abstract

With the aim of assessing whether the Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) are reliable measures of disease activity and function in patients with spondyloarthritides (SpAs), 341 patients with SpA (representing ankylosing spondylitis (14.5%), psoriatic arthritis (27.3%), enteropathic arthritis (6.3%), reactive arthritis (4.9%), and undifferentiated arthritis (46.5%) were asked to complete the BASDAI and BASFI. They were asked to report what their main problems associated with the disease were from a list of seven symptoms: fatigue, neck pain, upper back pain, lower back pain, stiffness, joint pain or swelling, and pain with pressure on joints. Correlations between the main symptoms experienced by patients with SpAs and the indices, defined by Spearman’s correlation coefficient, showed that BASDAI best correlated with neck pain [BASDAI 2 and total BASDAI score correlate strongly (p = 0.003 and 0.001, respectively), and BASDAI 1, 4, and 5 correlate moderately (p = 0.03, 0.02, and 0.01, respectively)], followed by stiffness, upper back pain, pain with pressure, lower back pain, fatigue, and joint pain. Stiffness correlated strongly with nine of ten items on BASFI (BASFI 1 showed moderate correlation, p = 0.01), followed by upper back pain (four of ten items correlated strongly, three of ten correlated moderately), neck pain (three of ten tasks correlated strongly and four of ten correlated moderately), lower back pain (one task correlated strongly, five moderately), joint pain and swelling (four tasks correlated moderately), fatigue (three tasks correlated moderately), and pain with pressure (two tasks correlated moderately). BASDAI and BASFI only partly reflect disease activity and patients’ functional capacity in SpAs. An alternate instrument is required to assess SpA disease activity and functional capacity more precisely.
Literature
1.
go back to reference Dougados M, van der Linden S, Juhlin R et al (1991) The European Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227CrossRefPubMed Dougados M, van der Linden S, Juhlin R et al (1991) The European Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227CrossRefPubMed
2.
go back to reference Brandt J, Khariouzov A, Listing J et al (2004) Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 31:531–538PubMed Brandt J, Khariouzov A, Listing J et al (2004) Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 31:531–538PubMed
3.
go back to reference Huerta-Sil G, Casasola-Vargas JC, Londono JD et al (2006) Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis 65:642–646CrossRefPubMed Huerta-Sil G, Casasola-Vargas JC, Londono JD et al (2006) Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis 65:642–646CrossRefPubMed
4.
go back to reference Collantes C, Zarco P, Munoz E et al (2006) Disease pattern of SpAs in Spain: description of the first national registry (REGISPONSER). J Rheumatol 33:2538–2540PubMed Collantes C, Zarco P, Munoz E et al (2006) Disease pattern of SpAs in Spain: description of the first national registry (REGISPONSER). J Rheumatol 33:2538–2540PubMed
5.
go back to reference Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
6.
go back to reference Calin A, Garrette S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis. The Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrette S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis. The Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
7.
go back to reference Spoorenberg A, van Tubergen A, Landewe R et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 44:789–795CrossRefPubMed Spoorenberg A, van Tubergen A, Landewe R et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 44:789–795CrossRefPubMed
8.
go back to reference Taylor WJ, Harrison AA (2004) Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 51:311–315CrossRefPubMed Taylor WJ, Harrison AA (2004) Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 51:311–315CrossRefPubMed
9.
go back to reference Maksymowych WP, Miller C, Velez M, Savage L (2007) To what degree do BASDAI and BASFI questionnaires address the most essential symptoms and disabilities of patients with ankylosing spondylitis? Ann Rheum Dis 66(suppl 2):405, abstract Maksymowych WP, Miller C, Velez M, Savage L (2007) To what degree do BASDAI and BASFI questionnaires address the most essential symptoms and disabilities of patients with ankylosing spondylitis? Ann Rheum Dis 66(suppl 2):405, abstract
10.
go back to reference Van der Heijde D, Lie E, Kvien TK, Sieper J, den Bosch Van, Listing J, Brown J, Landewe R, for the assessment of spondyloarthritis international society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818. doi:10.1136/ard2008.100826 CrossRefPubMed Van der Heijde D, Lie E, Kvien TK, Sieper J, den Bosch Van, Listing J, Brown J, Landewe R, for the assessment of spondyloarthritis international society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818. doi:10.​1136/​ard2008.​100826 CrossRefPubMed
Metadata
Title
The Bath Ankylosing Spondylitis Activity and Function Indices (BASDAI and BASFI) and their correlation with main symptoms experienced by patients with spondyloarthritis
Authors
Euthalia Roussou
Shahzabeen Sultana
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1411-9

Other articles of this Issue 8/2010

Clinical Rheumatology 8/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.